Search results
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Zacks via Yahoo News· 2 months agoAcadia Pharmaceuticals Inc. ACAD reported first-quarter 2024 earnings of 10 cents per share, beating...
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Zacks via Yahoo News· 4 months agoAcadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of...
Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now
Zacks via Yahoo News· 9 months agoSan Diego, CA-based Acadia Pharmaceuticals Inc. ACAD is a commercial biopharmaceutical company...
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Zacks via Yahoo News· 2 years agoMinerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking...
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
Zacks via Yahoo News· 2 years agoAcadia Pharmaceuticals Inc. ACAD reported a third-quarter 2022 loss of 17 cents per share, narrower...
Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study
Zacks via Yahoo News· 1 year agoData from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to...
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
Zacks via Yahoo News· 2 years agoMinerva Neurosciences NERV submitted a new drug application (“NDA”) to the FDA seeking approval of...
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
Zacks via Yahoo News· 2 years agoIt was a busy week for the volatile biotech sector, with important regulatory and pipeline updates...
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
Zacks via Yahoo News· 1 year agoThe biotech sector has been in focus in the past week with key pipeline and regulatory updates....
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Zacks via Yahoo News· 4 months agoIt was a busy week for the biotech sector with lots of study data readouts and regulatory approvals....